Kura Oncology Lands $50,000,000 New Funding Round

  • Feed Type
  • Date
    11/4/2015
  • Company Name
    Kura Oncology
  • Mailing Address
    11119 North Torrey Pines Road La Jolla, CA 92037 USA
  • Company Description
    At Kura Oncology (NASDAQ: KURA), we are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how we treat cancer.
  • Website
    http://www.kuraoncology.com
  • Transaction Type
    IPO
  • Transaction Amount
    $50,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    We currently expect that we will use the net proceeds from this offering as follows: to fund the completion of our Phase 2 clinical trials of tipifarnib in patients who have solid tumors with HRAS mutations and in patients with PTCL; to fund our planned Phase 2 clinical trial of tipifarnib in patients with lower risk MDS; to fund our ongoing ERK inhibitor program; to fund the initiation of our companion diagnostic program to aid in the selection of patients with HRAS mutant tumors and for additional indications; to fund research and preclinical development of our other product candidates; and for general corporate purposes, including general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of our intellectual property.
  • M&A Terms

Trending on Xconomy